Perioperative Management of Anticoagulation
|
|
- Cathleen Brittney Conley
- 5 years ago
- Views:
Transcription
1 Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at: 25 TH Annual Congress on November
2 Outline 1. Identify risk factors associated with perioperative bleeding versus thromboembolism 2. Discuss the decision pathway to consider in perioperative management of anticoagulation 3. Recognize key factors linked to the appropriate timing to withhold oral anticoagulants 4. Identify patients who warrant bridging of parenteral anticoagulation 5. Identify the appropriate timing to resume anticoagulation post operatively 6. Summarize the perioperative management of vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) 18/12/2017 2
3 Definitions and Abbreviations Definitions: - Perioperative: around the time of a surgery (before and after surgery) - Bridge anticoagulant therapy is the administration of a shortacting parenteral anticoagulant during the peri-operative period, when the patient is not taking chronic oral anticoagulant. Abbreviations: - OACs: Oral anticoagulants - DOACS: Direct oral anticoagulants - VKA: Vitamin K antagonists - TE: Thromboembolic Risk - DVT: Deep venous thrombosis - PE: Pulmonary embolism - VTE: Venous thromboembolism, including DVT & PE 18/12/2017 Circulation. 2012;125(12):e
4 Illustration of Perioperative Management of Anticoagulation Oral Anticoagulation Stop OAC before Surgery But what do we do in the meantime?? We give parenteral Anticoagulation that can be safely stopped before surgery Stop the parenteral anticoagulant before surgery Images taken from figures and multimedia from NEJM So we can safely operate with minimal bleeding 4
5 Background Patients receiving chronic oral anticoagulation for a variety of indications such as DVT, PE, Atrial Fibrillation, Secondary Prevention of Stroke, Mechanical Heart Valves Chronic oral anticoagulation includes: - VKAs (acenocoumarol, hydroxycoumarol or fluindione) - DOACS (rivaroxaban, apixaban and dabigatran) Around 15-20% of such patients require interruption of anticoagulation per year The decision of whether or not to bridge with parenteral agents is a clinical dilemma especially in lieu of minimal evidence. Circulation. 2012;126: /12/2017 Circulation. 2014;129: J Am Coll Cardiol 2015;66:
6 Background Guidelines on the perioperative management of anticoagulation: - American Heart Association, American College of Cardiology, Heart Rhythm Society - American College of Chest Physicians ** Recommendations are based on observational studies and expert opinion with minimal primary literature. Guideline consensus on 3 important principles: 1. OAC should not be interrupted for procedures with low bleeding risk. 2a. Patients at high risk for TE>>>bleeding risk need bridging 2b. Patients at low risk for TE or Bleeding risk >>>>TE no bridging 3. Intermediate- TE- risk cases should be managed individually based on patient- and procedure-specific risks for bleeding and TE. 18/12/2017 Chest 2012;141:e326S 50S. J Am Coll Cardiol 2014; 64:e
7 Step 1 in Perioperative Management of Anticoagulation- ASKING THE RIGHT QUESTIONS Asking the right questions helps gather important data for: - Improved communication - Informed decision making Key questions for pharmacists to ask: - Why are you taking chronic oral anticoagulation? - Who prescribed this medication to you? - How long have you been on it? - Have you ever had to stop this medication before? If yes for how long? 18/12/2017 7
8 Asking the right questions: How it helps Questions Patient Answers Is it a MUST to give BRIDGE THERAPY perioperatively?? (yes/no/not sure ) Why are you taking chronic oral anticoagulation Who prescribed this medication to you? Have you ever had to stop this medication before? If yes for how long? Why are you taking chronic oral anticoagulation I have a blood clot in my lungs (Pulmonary Embolus) that was found last week. My oncologist, but I m not sure why. I have a history of clots I think Yes, onetime I had to stop for a dental implant however 4 days later I went to the hospital with a clot in my leg. I had a blood clot in my lungs 4 years ago after having a huge car accident. Doctor told me it s from the accident but I don t have any other clotting abnormalities. 18/12/ YES YES / Not sureconfirm with oncologist YES NO
9 Case 1 HM is a 46 yo woman with a past medical history of atrial fibrillation and HTN Home medications include: - Bisoprolol 5mg po daily - Acenocoumarol 2mg po daily, most recent INR on was 2.2 (INR goal is 2-3) Her dentist informs her that she is going to undergo dental extraction on Which of the following is the most appropriate perioperative management of her anticoagulantion? a) Discontinue acenocoumarol 4 days before procedure b) Discontinue acenocoumarol 4 days before procedure and start enoxaparin when INR is less than 2 c) No need to discontinue acenocoumarol because it is a low bleeding risk procedure d) No need to discontinue acenocoumarol because it is a procedure that can be done on anticoagulation, but do not take acenocoumarol in the morning of the procedure 18/12/2017 9
10 Which procedures require: No need for Interruption of OAC N.B: very important that the OAC is not at peak activity or higher end of the therapeutic range during the procedure. For DOACS, wait 12 or 24 h after the last intake, depending on their specific regimen dosing (once or twice daily). For VKA, make sure INR is on the lower end of the therapeutic range ~ INR=2 18/12/ J Am Coll Cardiol 2015;66: European Heart Journal Cardiovascular Pharmacotherapy (2015) 1, Some examples of procedures that can be done without interruption of DOACs include skin cancer removal, joint injection, cataract removal, or tooth extraction in which an adequate local haemostasis is commonly possible. 2 Very important to coordinate with the surgeon or physician performing the procedure. They might not accept to operate 10 with on OAC!
11 Case 1 HM is a 46 yo woman with a past medical history of atrial fibrillation and HTN Home medications include: - Bisoprolol 5mg po daily - Acenocoumarol 2mg po daily, most recent INR on was 2.2 (INR goal is 2-3) Her dentist informs her that she is going to undergo dental extraction on Which of the following is the most appropriate perioperative management of her anticoagulantion? a) Discontinue acenocoumarol 4 days before procedure b) Discontinue acenocoumarol 4 days before procedure and start enoxaparin when INR is less than 2 c) No need to discontinue acenocoumarol because it is a low bleeding risk procedure d) No need to discontinue acenocoumarol because it is a procedure that can be done on anticoagulation, but do not take acenocoumarol in the morning of the procedure 18/12/
12 Perioperative Management of Anticoagulation Bleeding Risk Factors 1) Procedure 2) Patient-specific Thromboembolic Risk Depending on Indication and History 18/12/
13 Risk factors associated with perioperative bleeding versus thromboembolism BLEEDING RISK 1. Patient specific risk factors 2. Procedure specific risk of bleeding (low, moderate or high) 18/12/2017 THROMBOEMBOLISM RISK 1. Indication specific risk factors - Mechanical Heart Valves Mechanical vs bioprosthetic Aortic or mitral - Atrial Fibrillation CHADS2 CHAS2VAS2C - Venous Thromboembolism Timing of VTE Dubois et al. Thrombosis Journal (2017) 15:14 Circulation. 2017;135(24). J Am Coll Cardiol 2014; 64:e
14 Thromboembolic Risk Stratification Perioperatively 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s (J Am Coll Cardiol 2015;66: ) 14
15 Procedure-related-bleeding risk (VKA) perioperatively Surgeries and Procedures at an increased risk of bleeding if on antithrombotic therapy around the perioperative time: - Urologic surgery - Pacemaker or device implantation - Colonic polyp resection, typically of large polyps (1-2cm) - Surgery and procedures in highly vascular organs (ex. kidney, liver, and spleen) - Bowel resection - Major surgery with extensive tissue injury (eg, cancer surgery, joint arthroplasty, reconstructive plastic surgery) - Cardiac, intracranial, or spinal surgery- high risk bleeding 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s 15
16 Procedure-related-bleeding risk (DOACS) perioperatively Minor interventions: - Skin cancer removal, joint injection, cataract removal, or tooth extraction in which an adequate local haemostasis is commonly possible. Minor surgery: - Endoscopy with biopsy; prostate or bladder biopsy; electrophysiological study or simple radiofrequency catheter ablation; angiography; pacemaker or ICD implantation. Major surgery: - Complex leftsided ablation; spinal or epidural anaesthesia; lumbar diagnostic puncture; thoracicsurgery; abdominal surgery; major orthopaedic surgery; liver biopsy; transurethral prostate resection; kidney biopsy. 18/12/2017 European Heart Journal Cardiovascular Pharmacotherapy (2015) 1,
17 Patient Specific Bleeding Risk Score HAS-BLED Score is utilized in patients with Atrial Fibrillation Only High bleeding score 3 Identify and treat modifiable bleeding risk factors European Heart Journal (2010) 31, Hosp Pract. 2011;39:41 54 Eur Heart J 2016 Oct 7;37(38):
18 Institutional Checklists for Perioperative Anticoagulation: Decision Algorithms - Development of institutional guidelines and hospital policies for the perioperative management of Anticoagulants (DOACs or VKA) - A checklist including all aspects of the particular procedure and the patient characteristics that may increase the risks of bleeding or thrombosis should be available 18/12/2017 The perioperative checklist 1. The Thrombo-embolic risk of the patient 2. The bleeding Risk of the patient 3. Time of stopping the OAC before an invasive procedure 4. Specific considerations for some invasive procedures 5. When should bridge therapy with parenteral anticoagulants be suggested?? 6. When should we stop bridge therapy prior to the procedure? 7. Resuming an OAC after an invasive procedure or surgery Europace. 2015;17: Faraoni Crit Care. 2015;19:203 18
19 Published Decision Algorithm: Perioperative Management of Anticoagulation 18/12/2017 VOL. 69, NO. 7, THE AMERICAN COLLEGE OF CARDIOLOGY 19
20 When to Interrupt OAC?? Appropriate Timing to Withhold Anticoagulation Perioperatively VKA Type of procedure Physician comfort INR level DOACS Type of procedure Renal function (Creatinine Clearance according to cockgroft gault equation) 18/12/
21 VKA Perioperative Management When to stop How to bridge: based on INR When to stop bridge prior to the procedure When to resume OAC after the procedure 18/12/
22 Case 2 CC is a 42 yo man with a factor V Leiden, history of DVT x2 and recently diagnosed with a Pulmonary Embolus 20 days ago. Wt= 80kg and CrCl=94ml/min Maintained on acenocoumarol at home (INR goal 2-3). He is scheduled for a major orthopedic surgery on at 9am. His doctor advised to stop acenocoumarol 4 days before surgery. His Surgery is in 2 days and today his INR is 1.7. How would you manage this patient perioperatively? a) INR is subtherapeutic so no need to give parenteral anticoagulation b) Start enoxaparin 80mg SC bid now and give the last dose of enoxaparin on at 9 am (24 hours before surgery) c) Start enoxaparin 80mg SC bid now and give the last dose of enoxaparin on at 9 pm (12 hours before surgery) 18/12/
23 Appropriate timing to STOP VKA Before the Procedure If patients need temporary interruption of a VKA before surgery, recommended to stop VKAs approximately 5 days before surgery(grade 1C). Half life of VKA: - Warfarin (hydroxycoumarol): hours - Sintrom (acenocoumarol ): 8 to 11 hours Based on this discontinue acenocoumarol 4 days before surgery 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s 23
24 Identifying Patients who require Bridge Therapy 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s (J Am Coll Cardiol 2015;66: ) 24
25 Bridging Dose Regimens high-dose regimen (therapeutic-dose ) - enoxaparin 1 mg/kg bid or 1.5 mg/kg daily - tinzaparin 175 International Units/kg daily - IV UFH to reach 1.5 to 2.5 times the control aptt low-dose regimen (prophylactic-dose) - enoxaparin 30 mg bid or 40 mg daily - UFH 5,000-7,500 International Units bid intermediate-dose regimen (between high- and low-dose regimens) - enoxaparin 40 mg bid 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s 25
26 When to stop bridging prior to surgery? - If using therapeutic-dose IV UFH, stop UFH 4 to 6 h before surgery (Grade 2C). - If using therapeutic-dose SC LMWH, administer the last preoperative dose of LMWH approximately 24 h before surgery (Grade 2C). Minimize bleeding intraoperatively 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s 26
27 Case 2 CC is a 42 yo man with a factor V Leiden, history of DVT x2 and recently diagnosed with a Pulmonary Embolus 20 days ago. Wt= 80kg and CrCl=94ml/min Maintained on acenocoumarol at home (INR goal 2-3). He is scheduled for a major orthopedic surgery on at 9am. His doctor advised to stop acenocoumarol 4 days before surgery. His Surgery is in 2 days and today his INR is 1.7. How would you manage this patient perioperatively? a) INR is subtherapeutic so no need to give parenteral anticoagulation b) Start enoxaparin 80mg SC bid now and give the last dose of enoxaparin on at 9 am (24 hours before surgery) c) Start enoxaparin 80mg SC bid now and give the last dose of enoxaparin on at 9 pm (12 hours before surgery) 18/12/
28 Resumption of Anticoagulant post surgery After surgery: - In patients who require temporary interruption of a VKA before surgery, resume VKAs approximately 12 to 24 h after surgery (evening of or next morning) when there is adequate hemostasis (Grade 2C). - If using therapeutic-dose SC LMWH and are undergoing high-bleeding-risk surgery, resume therapeutic-dose LMWH 48 to 72 h after surgery (Grade 2C). CHEST 2012; 141(2)(Suppl):e326S e350s
29 DOACs Perioperative Management Looking at Procedure & Creatinine Clearance to decide when to stop DOAC Need to bridge?? When to resume DOAC 18/12/
30 Case 3 KK is a 50 yo man with a PMH of Atrial Fibrillation. CHADS2VASC Score is 1 due to having DM. Anticoagulation regimen: rivaroxaban 20mg po daily Procedure: cardiac catheterization via radial artery Wt=70kg CrCl= 67 ml/min Which of the following represents the best perioperative regimen? a) Give the last dose of rivaroxaban 3 days before surgery and start enoxaparin 70mg SC bid two days before surgery a) Give the last dose of rivaroxaban 3 days before surgery & no need for parenteral anticoagulation a) Give the last dose of rivaroxaban 2 days before surgery & no need to give parenteral anticoagulation b) No need to discontinue rivaroxban 18/12/
31 Appropriate Timing to Withhold DOACs Perioperatively 18/12/2017 European Heart Journal Cardiovascular Pharmacotherapy (2015) 1, doi: /ehjcvp/pvv002 31
32 Appropriate Timing to Withhold DOACs Perioperatively 18/12/2017 Journal of ClinicalAnesthesia(2016) 34,
33 Decision Algorithm: Perioperative Management of DOACs 18/12/2017 Circulation. 2017;135(24). doi: /cir
34 Case 3 KK is a 50 yo man with a PMH of Atrial Fibrillation. CHADS2VASC Score is 1 DM Anticoagulation regimen: rivaroxaban 20mg po daily Procedure: cardiac catheterization via radial artery Wt=70kg CrCl= 67ml/min Which of the following represents the best perioperative regimen? a) Give the last dose of rivaroxaban 3 days before surgery and start start enoxaparin 70mg SC bid two days before surgery b) Give the last dose of rivaroxaban 3 days before surgery & no need for parenteral anticoagulation c) Give the last dose of rivaroxaban 2 days before surgery & no need to give parenteral anticoagulation d) No need to discontinue rivaroxban 18/12/
35 Case 4 KK is a 80 yo man with a PMH of Atrial Fibrillation. CHADS2VASC Score is 7 ( due to his age, history of PAD, DM, HTN, ischemic stroke 6 weeks ago) Anticoagulation regimen: rivaroxaban 20mg po daily Procedure: major orthopedic surgery Wt=70kg CrCl= 67 Which of the following represents the best perioperative regimen? a) Give the last dose of rivaroxaban 3 days before surgery and start start enoxaparin 70mg SC bid two days before surgery b) Give the last dose of rivaroxaban 3 days before surgery & no need for parenteral anticoagulation c) Give the last dose of rivaroxaban 1 day before surgery d) No need to discontinue rivaroxban 18/12/
36 Decision Algorithm: Perioperative Management of NOACs 1. Bleeding risk 2. Thrombotic risk 3. Bleeding versus thrombotic risk 4. Stopping NOAC based on CrCl 5. Decide if parenteral agent is needed for bridge 18/12/2017 Circulation. 2017;135(24). doi: /cir
37 Case 4 KK is a 80 yo man with a PMH of Atrial Fibrillation. CHADS2VASC Score is 7 ( due to his age, history of PAD, DM, HTN, ischemic stroke 6 weeks ago) Anticoagulation regimen: rivaroxaban 20mg po daily Procedure: major orthopedic surgery Wt=70kg CrCl= 67 Platelets: 200,000cells/mm3 TE risk is high and bleeding risk is high But due to recent stroke TE>>>> Which of the following represents the best perioperative regimen? - Give the last dose of rivaroxaban 3 days before surgery and start enoxaparin 70mg SC bid two days before surgery - Give the last dose of rivaroxaban 3 days before surgery & no need for parenteral anticoagulation - Give the last dose of rivaroxaban 1 day before surgery - No need to discontinue rivaroxban 18/12/
38 Bridging Dose Regimens with DOACs is based on provider preference and minimal evidence high-dose regimen (therapeutic-dose ) - enoxaparin 1 mg/kg bid or 1.5 mg/kg daily - tinzaparin 175 International Units/kg daily - IV UFH to reach 1.5 to 2.5 times the control aptt low-dose regimen (prophylactic-dose) - enoxaparin 30 mg bid or 40 mg daily - UFH 5,000-7,500 International Units bid intermediate-dose regimen (between high- and low-dose regimens) - enoxaparin 40 mg bid 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s 38
39 When to stop bridging prior to surgery? - If using therapeutic-dose IV UFH, stop UFH 4 to 6 h before surgery (Grade 2C). - If using therapeutic-dose SC LMWH, administer the last preoperative dose of LMWH approximately 24 h before surgery (Grade 2C). 18/12/2017 CHEST 2012; 141(2)(Suppl):e326S e350s 39
40 Resumption of NOACs Postoperatively 18/12/2017 European Heart Journal Cardiovascular Pharmacotherapy (2015) 1, doi: /ehjcvp/pvv002 40
41 Summary on Periprocedural Management of VKA Steps: 1. Discontinue warfarin allowing for the clearance prior to the operation (INR returns to normal) 1. Warfarin or sintrom- discontinue ~4 days prior to surgery 2. In patients with medium to high risk of thromboembolism, once the anticoagulant is subtherapeutic, begin therapy with a short acting parenteral anticoagulant such as UFH or LMWH Bridging doses: prophylactic or treatment doses 3. Prior to surgery, discontinue the parenteral AC: UFH 6 hours prior to surgery LMWH 24h prior to surgery 4. Resume parenteral anticoagulant after surgery and overlap with warfarin
42 Summary on Perioperative Management of New Oral Anticoagulants 1. Evaluate Procedure Bleeding Risk 2. Evaluate the patient s thromboembolic risk 3. Factors to consider: Specific medication, CrCl & bleeding risk procedure 4. Options considered for perioperative mananagement: 1. Discontinuing the medication with predictable pharmacokinetics and NO BRIDGE or SWITCH to parenteral 2. Some physicians may opt to switch from a NOAC to a parenteral agent ( must follow the package insert guidance) 18/12/2017 BJS 2014; 101: Circulation. 2017;135(24). doi: /cir
43 Any Questions? 18/12/
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationNOACS/DOACS*: PERI-OPERATIVE MANAGEMENT
NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide guidance for the peri-operative management of patients who are receiving a newer direct oral anticoagulant (DOAC) and require an elective surgery/procedure.
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationt. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.
Name or Policy: Policy Number: 3364-133-116 Department: Approving Officer: Responsible Agent: cope: x Management of Anticoagulation with Invasive Procedures Pharmacy Chief Operating Officer Director of
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY
ANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-236-L01-P 0.1 CEU/1.0 hr Activity Type: Application-Based Learning Objectives for Pharmacists: Upon
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationPeriprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline
Periprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline A. Scope (disease/condition, treatment, clinical specialty) 1. Adult patients undergoing a procedure or surgery
More informationJoost van Veen Consultant Haematologist
Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationThe Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery. Alex C. Spyropoulos MD, FACP, FCCP, FRCPC
The Management of Patients on Chronic Oral Anticoagulant Therapy (VKA and DOAC) who Need Elective Surgery Alex C. Spyropoulos MD, FACP, FCCP, FRCPC Professor of Medicine Hofstra Northwell School of Medicine
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationCases & Panel Discussion
TSOACs What s the difference anyway? Controversies in selection and complications Augustus Hough, PharmD, BCPS (AQ-Cardiology) Clinical Pharmacy Specialist West Palm Beach VA Medical Center Larry Lopez
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More informationUpdate in Perioperative Anticoagulation and Antiplatelet management
Update in Perioperative Anticoagulation and Antiplatelet management Grand Rounds October 31, 2014 Brooke Hall, MD Steve Kornfeld, MD Bruce McLellan, MD Nothing to disclose Objectives Describe the updates
More informationThe Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.
The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban
More informationPreoperative Management of Patients Receiving Antithrombotics
Preoperative Management of Patients Receiving Antithrombotics Bleeding complications remain an important concern for most surgical procedures. Attempts to minimize the risk of these complications by removing
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationThe Pendulum of Bridging Periprocedural Anticoagulant Therapy. Alan K. Jacobson, MD Cardiology Section Loma Linda VA Medical Center Loma Linda, CA
The Pendulum of Bridging Periprocedural Anticoagulant Therapy Alan K. Jacobson, MD Cardiology Section Loma Linda VA Medical Center Loma Linda, CA Disclosures Department of Veterans Affairs Industry Relationships:
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationManagement of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationTo Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin
To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin Omprakash Pansara, MD Brian Kline, MD St. Joseph s Health Family Medicine Residency Program, Syracuse, NY Case 75yr old male, who
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationPerioperative Management of Warfarin Interruption
Perioperative Management of Warfarin Interruption Victoria Lambert, PharmD, CACP Medication Management Pharmacist William W. Backus Hospital Faculty Disclosures There are no actual or potential conflicts
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationIntrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway
Anticoagulant Cases 12 11 Intrinsic + Common = aptt 9 8 10 7 4 Extrinsic + Common = PT 5 2 Common Pathway 1 Xa Inhibitors rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) What is true regarding
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationEAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY
EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent
More informationPeri-Procedural Management of Antithrombotic Agents
u Peri-Procedural Management of Antithrombotic Agents An Integrated Care Pathway of the Collaborative Care Network Subject Matter Experts: Will Maxted, MD Veronica Kerner, PharmD Pathway Custodian: Pat
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationDirect Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More information8/16/2016. Disclosures. Is Uninterrupted OAC Standard of Care for AF Ablation? CHRS 2016, San Francisco. Risk of Stroke Peri-Ablation
Disclosures Is Uninterrupted OAC Standard of Care for AF Ablation? CHRS 2016, San Francisco Atul Verma, MD FRCPC FHRS Director, Heart Rhythm Program Southlake Regional Health Centre Newmarket, Ontario,
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationThrombosis Canada Clinical Tools. Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation
Thrombosis Canada Clinical Tools Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation Dr. Benjamin Bell, MD FRCPC Staff General Internist North York General Hospital Lecturer,
More informationActa Orthopaedica 2016; 87 (Id.no 10437) Supplementary article data (1/5)
Acta Orthopaedica 2016; 87 (Id.no 10437) Supplementary article data (1/5) Supplementary article data Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists
More informationDate 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension Direct Line tadamson(anhs.
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224 556689
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationPMB and the management of patients on oral anticoagulants
PMB and the management of patients on oral anticoagulants Domenico Prisco DMSC, Università di Firenze SOD Medicina Interna Interdisciplinare AOU Careggi, Firenze Il/La sottoscritto/a, in qualità di Relatore
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationPerioperative management of Anticoagulant and Antiplatelet medication GL067
Perioperative management of Anticoagulant and Antiplatelet medication GL067 Approval Approval Group Job Title, Chair of Committee Date Anaesthetics Clinical Governance Chair, Anaesthetics Clinical November
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationManagement of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More information